People: Crinetics Pharmaceuticals Inc (CRNX.OQ)

CRNX.OQ on NASDAQ Stock Exchange Global Select Market

12:19am IST
Change (% chg)

$-1.04 (-6.54%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Struthers, R. Scott 

Dr. R. Scott Struthers Ph.D. serves as President, Chief Executive Officer, Director of the Company. Prior to Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences, Inc., from 1998 to 2008. At Neurocrine, he initiated and led the company’s efforts to discover and develop orally active, nonpeptide GnRH antagonists, including elagolix. Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions for the life sciences and higher education markets and led contract research efforts at Biosym Technologies, from 1992 to 1995, to develop and apply computational tools for drug discovery. Dr. Struthers is also a co-founder of the San Diego Entrepreneurs Exchange, a nonprofit organization which he has served on the board of directors of since January 2009. He holds a Ph.D. in physiology and pharmacology from the University of California, San Diego based on the work he performed at the Salk Institute for Biological Studies. Dr. Struthers’ knowledge of our business, as well as his extensive development and clinical experience, contributed to our board of directors’ conclusion that he should serve as a director of our company.

Basic Compensation

Total Annual Compensation, USD 541,708
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 3,224,950
Fiscal Year Total, USD 3,766,660

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Wendall Wierenga


R. Scott Struthers


Marc Wilson


Adriana Cabre


Alan Krasner


Ajay Madan

As Of  31 Dec 2019